Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis.


Journal

Journal of the National Comprehensive Cancer Network : JNCCN
ISSN: 1540-1413
Titre abrégé: J Natl Compr Canc Netw
Pays: United States
ID NLM: 101162515

Informations de publication

Date de publication:
09 2020
Historique:
received: 03 02 2020
accepted: 25 03 2020
entrez: 4 9 2020
pubmed: 5 9 2020
medline: 5 11 2021
Statut: ppublish

Résumé

It remains unknown to what extent hepatocellular carcinomas (HCCs) are detected very early (T1 stage; ie, unifocal <2 cm) in the United States. The aim of this study was to investigate the trends and factors associated with very early detection of HCC and resultant outcomes. Patients with HCC diagnosed from 2004 through 2014 were identified from the National Cancer Database. Logistic regression was used to identify factors associated with T1 HCC detection, and Cox proportional hazard analyses identified factors associated with overall survival among patients with T1 HCC. Of 110,182 eligible patients, the proportion with T1 HCC increased from 2.6% in 2004 to 6.8% in 2014 (P<.01). The strongest correlate of T1 HCC detection was receipt of care at an academic institution (odds ratio, 3.51; 95% CI, 2.31-5.34). Older age, lack of insurance, high Model for End-Stage Liver Disease (MELD) score, high alpha-fetoprotein, increased Charlson-Deyo comorbidity score, and nonsurgical treatment were associated with increased mortality, and care at an academic center (hazard ratio [HR], 0.27; 95% CI, 0.15-0.48) was associated with reduced mortality in patients with T1 HCC. Liver transplantation (HR, 0.27; 95% CI, 0.20-0.37) and surgical resection (HR, 0.67; 95% CI, 0.48-0.93) were independently associated with improved survival compared with ablation. This is the first study to examine the trend of T1 HCC using the National Cancer Database, which covers approximately 70% of all cancer diagnoses in the United States, using robust statistical analyses. Limitations of the study include a retrospective study design using administrative data and some pertinent data that were not available. Despite increases over time, <10% of HCCs are detected at T1 stage. The strongest correlates of survival among patients with T1 HCC are receiving care at an academic institution and surgical treatment.

Sections du résumé

BACKGROUND
It remains unknown to what extent hepatocellular carcinomas (HCCs) are detected very early (T1 stage; ie, unifocal <2 cm) in the United States. The aim of this study was to investigate the trends and factors associated with very early detection of HCC and resultant outcomes.
METHODS
Patients with HCC diagnosed from 2004 through 2014 were identified from the National Cancer Database. Logistic regression was used to identify factors associated with T1 HCC detection, and Cox proportional hazard analyses identified factors associated with overall survival among patients with T1 HCC.
RESULTS
Of 110,182 eligible patients, the proportion with T1 HCC increased from 2.6% in 2004 to 6.8% in 2014 (P<.01). The strongest correlate of T1 HCC detection was receipt of care at an academic institution (odds ratio, 3.51; 95% CI, 2.31-5.34). Older age, lack of insurance, high Model for End-Stage Liver Disease (MELD) score, high alpha-fetoprotein, increased Charlson-Deyo comorbidity score, and nonsurgical treatment were associated with increased mortality, and care at an academic center (hazard ratio [HR], 0.27; 95% CI, 0.15-0.48) was associated with reduced mortality in patients with T1 HCC. Liver transplantation (HR, 0.27; 95% CI, 0.20-0.37) and surgical resection (HR, 0.67; 95% CI, 0.48-0.93) were independently associated with improved survival compared with ablation. This is the first study to examine the trend of T1 HCC using the National Cancer Database, which covers approximately 70% of all cancer diagnoses in the United States, using robust statistical analyses. Limitations of the study include a retrospective study design using administrative data and some pertinent data that were not available.
CONCLUSIONS
Despite increases over time, <10% of HCCs are detected at T1 stage. The strongest correlates of survival among patients with T1 HCC are receiving care at an academic institution and surgical treatment.

Identifiants

pubmed: 32886898
doi: 10.6004/jnccn.2020.7564
pii: jnccn20047
doi:
pii:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1210-1220

Subventions

Organisme : NCI NIH HHS
ID : R01 CA222900
Pays : United States

Auteurs

Ju Dong Yang (JD)

Division of Digestive and Liver Diseases.
Comprehensive Transplant Center.
Samuel Oschin Comprehensive Cancer Institute, and.

Michael Luu (M)

Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, West Hollywood, California; and.

Amit G Singal (AG)

Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas.

Mazen Noureddin (M)

Division of Digestive and Liver Diseases.
Comprehensive Transplant Center.

Alexander Kuo (A)

Division of Digestive and Liver Diseases.
Comprehensive Transplant Center.

Walid S Ayoub (WS)

Division of Digestive and Liver Diseases.
Comprehensive Transplant Center.

Vinay Sundaram (V)

Division of Digestive and Liver Diseases.
Comprehensive Transplant Center.

Honore Kotler (H)

Comprehensive Transplant Center.

Irene K Kim (IK)

Comprehensive Transplant Center.

Tsuyoshi Todo (T)

Comprehensive Transplant Center.

Georgios Voidonikolas (G)

Comprehensive Transplant Center.

Todd V Brennan (TV)

Comprehensive Transplant Center.

Kambiz Kosari (K)

Comprehensive Transplant Center.

Andrew S Klein (AS)

Comprehensive Transplant Center.

Andrew Hendifar (A)

Samuel Oschin Comprehensive Cancer Institute, and.

Shelly C Lu (SC)

Division of Digestive and Liver Diseases.
Samuel Oschin Comprehensive Cancer Institute, and.

Nicholas N Nissen (NN)

Comprehensive Transplant Center.
Samuel Oschin Comprehensive Cancer Institute, and.

Jun Gong (J)

Samuel Oschin Comprehensive Cancer Institute, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH